Class / Patent application number | Description | Number of patent applications / Date published |
514548000 | Ring is alcohol moiety | 43 |
20080242724 | Ibopamine Maleate, Method for Preparing it and Pharmaceutical Compositions Containing It - Ibopamine malcate salt (1:1), method for preparing it and pharmaceutical composition containing it. | 10-02-2008 |
20080242725 | Pharmaceutical Composition - Stabilized pharmaceutical compositions comprising polymorphs of active pharmaceutical ingredients susceptible to conversion to alternate polymorph forms are prepared by a process of wet granulation in which the ratios of active, fillers, and granulating liquid are controlled in order to avoid polymorphic interconversions. | 10-02-2008 |
20080280979 | Methods and Compositions of Derivatives of Probucol for the Treatment of Diabetes - This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof. | 11-13-2008 |
20080293812 | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates - Pamoic acid or its derivatives of formula (I) are used to treat diseases characterized by deposits of amyloid aggregates. | 11-27-2008 |
20080300304 | Ginger Fraction For Inhibiting Human Cyp Enzymes - The present invention relates to a process for preparing a ginger fraction, the fraction prepared by this process and the use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P450 3A4, CYP3A4) for positively influencing the oral bioavailability and pharmacokinetics of active substances. | 12-04-2008 |
20080300305 | METHOD OF PURIFYING PRAVASTATIN - The present invention provides pure pravastatin compositions and pure compactin compositions, and methods for the preparation thereof. | 12-04-2008 |
20080319068 | Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same - A polymer of aspirin is provided by the present invention. Methods of making and using the same are also provided. | 12-25-2008 |
20090076148 | DEUTERIUM-ENRICHED PRAVASTATIN - The present application describes deuterium-enriched pravastatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090105338 | DEUTERIUM-ENRICHED GABEXATE MESYLATE - The present application describes deuterium-enriched gabexate mesylate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 04-23-2009 |
20100004333 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS - The present invention relates to compounds and methods for the treatment of cardiovascular diseases and disorders. Compounds according to the present invention may comprise an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer comprises two groups selected from selenium, sulfur, S(O) and S(O) | 01-07-2010 |
20100125103 | COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES - Disclosed is a pharmaceutical composition containing obovatol represented by Formula 1 and its derivatives. The obovatol and its derivatives effectively increase the activity of AMPK (AMP-activated protein kinase) that plays an important role in diabetes and metabolic syndrome, and thus may be variously used in treating diabetes and metabolic syndrome. | 05-20-2010 |
20110015269 | PROCESS FOR THE PREPARATION OF DIACERIN - The invention concerns a new process for the preparation of high purity diacerein, by oxidisation of the protected aloe-emodin in the presence of an oxidising system and radical catalyst and subsequent substitution of the protector groups with acetyl groups. | 01-20-2011 |
20110021631 | Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms - A process is described for the preparation of a pharmaceutical comprising an active pharmaceutical ingredient capable of existing in multiple polymorphic forms, wherein the process comprises a step of preparation of a wet phase comprising the active pharmaceutical ingredient and microcrystalline cellulose and a liquid, wherein in the wet phase has a weight ratio of active pharmaceutical ingredient to microcrystalline cellulose above 1.0 or a weight ratio of active pharmaceutical ingredient to liquid above 1.0. | 01-27-2011 |
20110112190 | ORALLY ACTIVE CURCUMINOID COMPOUNDS - The invention discloses a compound of formula (I) wherein, at least one of R | 05-12-2011 |
20110166225 | ORAL LIQUID COMPOSITIONS OF RHEIN OR DIACEREIN - The invention relates to liquid pharmaceutical compositions for oral administration comprising rhein or diacerein, or salts or esters or prodrugs thereof and processes for preparing such compositions. | 07-07-2011 |
20110166226 | PROCESS FOR OBTAINING AN EXTRACT RICH IN ROSMARINIC ACID (RA) FROM THE PLANT ORIGANUM VULGARE AND ITS USE FOR THE TREATMENT OF DIABETES - Diabetes consists of a worldwide public health concern that leads to high levels of morbidity and premature mortality and affects millions of people in countries of any level of development. It is estimated that there are more than 150 million people with diabetes in the world, wherein projections from the World Health Organization (WHO) for 2025 such amount may get to 300 million cases. | 07-07-2011 |
20110230556 | Diglycidic Ether Derivative Therapeutics and Methods for Their Use - This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided. | 09-22-2011 |
20110245340 | Screening Method for Identifying Patients at Risk of Adverse Hepatologic Events - This present invention provides methods and kits for identifying patients at risk of suffering from a drug induced liver injury, particularly for an antioxidant drug, or for identifying patients who are suffering from early stages of a liver disorder by assessing the levels of apolipoprotein in a sample of the patient and comparing that to a reference value. The reference value is predetermined by identifying a population sample and determining an upper limit of normal value. This value is then used as a reference point for comparison of apolipoprotein levels from patient samples. In one embodiment, apolipoprotein levels are combined with ATL and/or total bilirubin levels for predicting liver damage, hepatotoxicity or hepatic events after drug administration. | 10-06-2011 |
20110245341 | PROCESS FOR THE PREPARATION OF NON-GENOTOXIC DIACETYLRHEIN (DIACEREIN) AND FORMULATIONS COMPRISING NON-GENOTOXIC DIACETYLRHEIN - The present invention is directed to a process for producing non-genotoxic Diacetylrhein (Diacerein), comprising: i) transformation of raw Diacerein (or raw Rhein), into a water-soluble salt; ii) adsorption of the salt Diacerein (or Rhein) solution on a hydrophobic resin; iii) washing with an appropriate solvent to eliminate the impurities (in particular the genotoxic impurities); iv) elution to recover Diacereinor Rhein; v) if the process is applied to Rhein, its transformation to Diacerein by acetylation; vi) acidification of purified Diacerein and its recovery, and drying. The invention is also directed to non-genotoxic Diacerein obtained by the process of the invention, in which the total content of genotoxic impurities is below 1 ppm, and suitable for the preparation of pharmaceutical formulations, in particular capsules, for human and veterinary use, in agreement with the current Health Authorities request. | 10-06-2011 |
20110275713 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements - This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements. | 11-10-2011 |
20110288170 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS - Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided. | 11-24-2011 |
20120088829 | Formulations of Ubiquinol and Resveratrol Esters - Disclosed herein are stabilized aqueous formulations comprising a ubiquinol ester/diester or resveratrol ester, and a micelle-forming surfactant, and methods for preparing the formulations. In one embodiment, the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 12 months. | 04-12-2012 |
20120149772 | PROCESS FOR THE PREPARATION OF FESOTERODINE OR A SALT THEREOF - A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities. | 06-14-2012 |
20120165406 | BIS-TRIFLUOROMETHYL HONOKIOL ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are hexafluoro-honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative hexafluoro-honokiol analogs include hexafluoro-honokiol, analogs in which one or both hydroxy groups are replaced with dichloroacetate esters, and analogs with increased fluorination. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers. | 06-28-2012 |
20120295973 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES - This present invention provides methods and pharmaceutical compositions for the treatment or prophylaxis of diabetes and related disorders, comprising the administration of an effective amount of a monoester of probucol, particularly the monosuccinic acid ester, or a pharmaceutically acceptable salt or derivative thereof. | 11-22-2012 |
20120316236 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF - A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: | 12-13-2012 |
20130030051 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 01-31-2013 |
20130046015 | Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease - Compositions and methods are provided for the treatment of IL-17-type inflammatory demyelinating diseases with inhibitors of granulocyte function, e.g. elastase inhibitors. Diseases of interest include multiple sclerosis, neuromyelitis optica, animal models of such diseases, etc. In some embodiments pharmaceutical formulations comprising an elastase inhibitor in an effective dose for treatment of IL-17-type inflammatory demyelinating disease and a pharmaceutically acceptable excipient are provided. Patients may be classified into subtypes prior to treatment, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. | 02-21-2013 |
20130072559 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS - Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided. | 03-21-2013 |
20130072560 | RETINAL DERIVATIVES AND METHODS FOR THE USE THEREOF FOR THE TREATMENT OF VISUAL DISORDERS - Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided. | 03-21-2013 |
20130072561 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION - A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxyiates of C | 03-21-2013 |
20130072562 | TUMOR NECROSIS FACTOR INHIBITORS - The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions. | 03-21-2013 |
20130085180 | ORAL BIOAVAILABLE PENTAMIDIN PRODRUGS FOR TREATMENT OF DISEASES - The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria. | 04-04-2013 |
20140135393 | SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA - The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation. | 05-15-2014 |
20140155480 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence - Scyllo-Inositol derivatives represented by structural formula II are described, wherein at least one and not more than five of R | 06-05-2014 |
20140221484 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 08-07-2014 |
20140221485 | LIPOPHILIC DOPAMINE DERIVATIVES AND THEIR USE - The invention provides novel lipophilic dopamine derivatives with improved stability and physiological half-life. The compounds may be used for organ and tissue preservation during storage and transport, or in the pre-treatment of organ and tissue donor or recipients. Moreover, they may be used as therapeutic agents for the prevention or treatment of ischaemia-related pathological conditions. | 08-07-2014 |
20140235714 | CANCER THERAPY - The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both. | 08-21-2014 |
20140371311 | INGENANE-TYPE DITERPENE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING VIRAL INFECTIOUS DISEASES CONTAINING SAME - The present invention relates to an injenane-type diterpene compound derived from | 12-18-2014 |
20150099806 | COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF - A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: | 04-09-2015 |
20150111965 | ORALLY BIOAVAILABLE PENTAMIDINE PRODRUGS FOR THE TREATMENT OF DISEASES - The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria. | 04-23-2015 |
20150342918 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing ThI cytokine expression, and decreasing Th2 cytokine expression. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols or therapeutic agents used to treat opportunistic infections due to HIV in mammalian subjects. | 12-03-2015 |
20150344403 | FLUORINATED CBD COMPOUNDS, COMPOSITIONS AND USES THEREOF - The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments. | 12-03-2015 |